Li Gong1, Dongxia Zheng1, Jiangzi Yuan1, Liou Cao1, Zhaohui Ni1, Wei Fang2. 1. Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai, 200127, People's Republic of China. 2. Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Shanghai, 200127, People's Republic of China. fangwei_sh@126.com.
Abstract
PURPOSE: To investigate the correlation between elevated serum sclerostin levels and chronic kidney disease outcomes for patients receiving peritoneal dialysis (PD). METHODS: We performed a prospective observational study in stable PD patients. Serum sclerostin levels were determined via enzyme immunoassay, and median levels of sclerostin were used to divide patients into high and low sclerostin groups. New-onset cardiovascular events (CVEs) and cardiovascular mortality were evaluated during a 6-year follow-up period. RESULTS: Ninety-eight patients [mean age 52.5 ± 10.9 years, 49% males, 21.4% diabetic, median dialysis vintage 40.7 (range 17.9-72.2) months] were recruited. Compared with those in the low sclerostin group, patients in the high sclerostin group demonstrated higher levels of total-cholesterol, NT-proBNP, and osteoprotegerin (all P < 0.05). During the 6-year study period, 25 CVEs and 17 cardiovascular deaths occurred in the high sclerostin group, whereas 11 CVEs and four cardiovascular deaths occurred in the low sclerostin group. A Cox regression analysis determined that high sclerostin levels significantly increased the risk for CVEs (HR 2.475, 95% CI 1.116-5.489, P = 0.026) and cardiovascular death (HR 3.484, 95% CI1.134-10.706, P = 0.029), after multiple adjustments were made. CONCLUSIONS: Our data suggest that high sclerostin levels may predict the onset of CVEs and cardiovascular mortality among PD patients.
PURPOSE: To investigate the correlation between elevated serum sclerostin levels and chronic kidney disease outcomes for patients receiving peritoneal dialysis (PD). METHODS: We performed a prospective observational study in stable PDpatients. Serum sclerostin levels were determined via enzyme immunoassay, and median levels of sclerostin were used to divide patients into high and low sclerostin groups. New-onset cardiovascular events (CVEs) and cardiovascular mortality were evaluated during a 6-year follow-up period. RESULTS: Ninety-eight patients [mean age 52.5 ± 10.9 years, 49% males, 21.4% diabetic, median dialysis vintage 40.7 (range 17.9-72.2) months] were recruited. Compared with those in the low sclerostin group, patients in the high sclerostin group demonstrated higher levels of total-cholesterol, NT-proBNP, and osteoprotegerin (all P < 0.05). During the 6-year study period, 25 CVEs and 17 cardiovascular deaths occurred in the high sclerostin group, whereas 11 CVEs and four cardiovascular deaths occurred in the low sclerostin group. A Cox regression analysis determined that high sclerostin levels significantly increased the risk for CVEs (HR 2.475, 95% CI 1.116-5.489, P = 0.026) and cardiovascular death (HR 3.484, 95% CI1.134-10.706, P = 0.029), after multiple adjustments were made. CONCLUSIONS: Our data suggest that high sclerostin levels may predict the onset of CVEs and cardiovascular mortality among PDpatients.
Authors: S Thambiah; R Roplekar; P Manghat; I Fogelman; W D Fraser; D Goldsmith; Geeta Hampson Journal: Calcif Tissue Int Date: 2012-04-21 Impact factor: 4.333
Authors: Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi Journal: J Bone Miner Res Date: 2012-08 Impact factor: 6.741
Authors: Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty Journal: J Bone Miner Res Date: 2008-06 Impact factor: 6.741
Authors: Monika Frysz; Ingrid Gergei; Hubert Scharnagl; George Davey Smith; Jie Zheng; Deborah A Lawlor; Markus Herrmann; Winfried Maerz; Jon H Tobias Journal: J Bone Miner Res Date: 2021-12-09 Impact factor: 6.390